Development of [⁸⁹Zr]Zr-hCD103.Fab01A and [⁶⁸Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET.

"Declarations Ethics approval and consent to participateAnimal experiments were planned and performed under approval of the Institutional Animal Care and Use Committee of the University of Groningen in agreement with EU Directive 2010/63/EU (IvD: 16395-01-019). The study was also carried out in compliance with the ARRIVE guideline. Consent for publicationNot applicable. Competing interestsA. Kol, S. van Duijnhoven, H. van Eenennaam, H.W. Nijman and M. de Bruyn are co-inventors on a patent owned by Aduro Biotech and University Medical Center Groningen that describes antibodies targeting CD103 (patent no. 62/704258). Competing interests A. Kol, S. van Duijnhoven, H. van Eenennaam, H.W. Nijman and M. de Bruyn are co-inventors on a patent owned by Aduro Biotech and University Medical Center Groningen that describes antibodies targeting CD103 (patent no. 62/704258)."

"Funding The collaboration project is financed by the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships. We also wish to acknowledge financial support of Chinese Scholarship Council CSC (201906210060)."